Extreme Movers: GPT-6's picks for 2026-10-09
GPT-6 picked HAE, ARGX, AAOI, HUT, COCO for a 1-day horizon. Average directional return: -0.51%. Directions called correctly: 40%.
| Experiment | Extreme Movers |
|---|---|
| Model | GPT-6 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -0.51% |
| Directions called correctly | 40% |
| Benchmark return | +0.22% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | HAE | up | +0.45% | +0.45% | 72% | +0.23% | Yes |
| 2 | ARGX | down | +1.30% | -1.30% | 67% | -1.52% | No |
| 3 | AAOI | up | -7.16% | -7.16% | 62% | -7.38% | No |
| 4 | HUT | up | +6.64% | +6.64% | 60% | +6.42% | Yes |
| 5 | COCO | down | +1.20% | -1.20% | 57% | -1.42% | No |
The model's market view
Cautious and highly selective. The October 8, 2026 source session saw the Nasdaq decline approximately 1.3%, with pressure on AI infrastructure, optical networking, biotechnology, and cryptocurrency-sensitive equities. Higher Treasury yields, elevated oil prices, and concerns about AI investment returns weakened risk appetite. Five liquid, US-listed common stocks are selected from the previous session's leading gainers and losers. HAE has the strongest substantive positive catalyst, while ARGX faces confirmed clinical disappointment. AAOI and HUT offer potential oversold rebounds, whereas COCO's sharp recovery appears vulnerable to profit-taking. Rankings emphasize catalyst quality, expected next-session directional return, liquidity, and reversal risk rather than simply selecting the largest percentage moves. All five latest available quotes are from October 9, 2026, between 09:35 and 10:05 EDT. Exact 20-session average daily dollar volumes were not independently established. Published 20-day average share volumes and price histories suggest that all five comfortably exceed the $20 million liquidity floor, but the exact dollar-volume screening values remain unverified. The primary evaluation metric is the mean signed next-session return, with positive signs for predicted increases and negative signs for predicted decreases. Directional accuracy is the fraction of the five forecasts whose predicted directions are correct. Neither metric can be calculated before the forecast window closes. No future price information is used.
Why each pick
HAE
Rank 1: Haemonetics gained 17.46% during the October 8 regular session, closing at $119.47 from $101.71. The catalyst is substantive: CSL Plasma confirmed plans to transition its existing US plasma collection centers to Haemonetics equipment, expanding the commercial opportunity under an existing supply relationship. The announcement supports a potentially material increase in recurring equipment and consumables revenue. Multiple analysts subsequently raised price targets, including BofA, Mizuho, and Barrington to $140. This follow-through strengthens the fundamental explanation for the move. The hypothesis is continuation because institutional analysts are incorporating the expanded agreement into future revenue estimates. Risks include substantial gains already reflected in the share price, an RSI above 76, uncertain implementation timing, and profit-taking following the initial repricing. The latest verified intraday quote is $119.86 at 10:05 EDT on October 9, approximately seven minutes before the prediction timestamp. Published 20-day average share volume is 638,014, supporting substantial liquidity, but exact 20-day average daily dollar volume was not independently verified. The displayed market capitalization is a current quote-page figure rather than an independently reconstructed October 8 closing valuation. Sources: StockAnalysis for live price, market capitalization, historical returns, and average share volume; Barron's and company-related disclosures for the substantive CSL agreement.
ARGX
Rank 2: Argenx declined 11.83% on October 8, closing at $818.63 from $928.44. The substantive negative catalyst was discontinuation of the Phase 3 UNITY study evaluating Vyvgart in Sjogren's disease. Terminating a late-stage clinical program reduces the expected value of a potential commercial indication and creates uncertainty around the breadth of the company's autoimmune pipeline. Morgan Stanley subsequently reduced its price target from $1,250 to $1,140 while maintaining an Overweight rating, illustrating the distinction between a negative near-term development and the company's continuing commercial value. The hypothesis is continuation downward because institutional portfolio adjustments and reassessment of the clinical pipeline may persist beyond the announcement session. Risks include an oversold technical condition, the company's existing commercial franchise, a substantial cash position, and bargain buying after the double-digit decline. The latest verified intraday quote is $812.58 at 09:56 EDT on October 9, approximately 17 minutes before the prediction timestamp. Published 20-day average share volume is 381,122. Exact 20-day average dollar volume was not verified. The market capitalization is the quote-page estimate rather than a separately established October 8 close figure. Sources: StockAnalysis for US-listed ARGX prices and market statistics, and Investors Business Daily for the clinical catalyst.
AAOI
Rank 3: Applied Optoelectronics fell 13.58% during the October 8 regular session, closing at $105.90 from $122.54. The decline coincided with broad weakness among optical networking and AI infrastructure suppliers. The company had experienced a substantial prior rally, making it particularly sensitive to concerns about AI infrastructure spending and sector valuations. The company also announced completion of a previously disclosed at-the-market equity offering on October 5. That announcement is verifiable, but a direct causal relationship between the offering completion and the October 8 decline has not been established. The October 8 move therefore appears predominantly sector-driven and positioning-related rather than attributable to a newly confirmed deterioration in operating fundamentals. The prediction is reversal upward because the selloff may have overshot near-term fundamental implications. A positive opening indication on October 9 is contextual evidence only and is not used to classify the hypothesis. Risks include continuing AI sector deleveraging, additional valuation compression, high volatility, and continued selling by momentum-oriented investors. The latest verified intraday quote is $109.25 at 09:56 EDT on October 9, approximately 17 minutes before prediction. Published 20-day average share volume is 8,401,838, but exact 20-day average dollar volume was not established. The displayed market capitalization is from the current quote page, not a reconstructed October 8 close. Sources: StockAnalysis for trading data and corporate announcements; Reuters for broader AI-related market pressure.
HUT
Rank 4: Hut 8 declined 10.87% on October 8, closing at $79.59 from $89.30. The stock was among the major losers in a session characterized by falling cryptocurrency prices, rising Treasury yields, and broad pressure on speculative technology investments. Other cryptocurrency-related equities also experienced substantial declines. The primary catalyst is therefore broad risk reduction rather than a separately confirmed negative company-specific operating announcement. Hut 8 also announced the scheduling of its third-quarter earnings release, but that routine announcement is not evidence of operational deterioration. The hypothesis is an upward reversal because the combination of cryptocurrency sensitivity, substantial share-price volatility, and heavy selling can produce sharp short-term recoveries when selling pressure moderates. The prediction does not treat the positive October 9 opening indication as continuation; continuation and reversal are defined exclusively relative to the negative October 8 return. Risks include further Bitcoin weakness, funding concerns surrounding capital-intensive digital infrastructure development, high financial leverage, and renewed technology-sector selling. The latest verified intraday quote is $80.19 at 10:04 EDT on October 9, approximately nine minutes before the prediction timestamp. Published 20-day average share volume is 4,804,992, although exact 20-day average daily dollar volume remains unverified. The market capitalization is a current quote-page estimate rather than a separately calculated October 8 closing value. Sources: StockAnalysis for share prices and company information; contemporaneous market reporting for cryptocurrency-related weakness.
COCO
Rank 5: Vita Coco advanced 10.52% on October 8, closing at $55.98 from $50.65. The move followed a 7.03% decline on October 7 and represented a substantial recovery within two trading sessions. No definitive company-specific announcement explaining the October 8 rally was established. Oppenheimer initiated coverage with an Outperform rating and a $70 price target earlier in October, but this does not establish causation for the October 8 move. BofA subsequently reduced its price target from $85 to $72 while maintaining a Buy recommendation, illustrating continuing valuation uncertainty. The catalyst classification is therefore speculative or positioning-driven rather than an established fundamental event. The hypothesis is a downward reversal because the rapid recovery may invite profit-taking, particularly after the stock rebounded sharply without an independently confirmed new fundamental catalyst. Risks include sustained institutional demand, supportive beverage-category fundamentals, and a continued rebound following the preceding decline. The latest verified intraday quote is $55.55 at 09:35 EDT on October 9, approximately 38 minutes before prediction. This is a less fresh quote than those used for the other four selections. Published 20-day average share volume is 1,384,605, but the exact average daily dollar volume was not independently calculated. The displayed capitalization is a current quote-page value, not a separately verified October 8 close figure. Sources: StockAnalysis for price history, capitalization, analyst commentary, and trading statistics.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Muse Spark 1.1 | HAE, CSGP, AAOI, MXL, ARGX | +0.31% | 60% |
| Gemini 1.5 Pro | HAE, COHR, COCO, CSGP, GLW | -0.95% | 40% |
| Perplexity | HUM, COHR, VZ, DAL, LITE | -2.12% | 0% |
| Grok 4.5 | HUM, CCI, TMUS, T, ASTS | +0.44% | 60% |
| Claude Sonnet 5.5 | CMG, HAE, COHR, CSGP, ORCL | +0.45% | 60% |
| DeepSeek | HUM, CCI, TMUS, T, DAL | +0.92% | 60% |
Written up on ForecastNest Insights: Extreme Movers: GPT-6's picks for 2026-10-09.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.